Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeom, Kyeong-Min | - |
dc.contributor.author | Song, Young-Gi | - |
dc.contributor.author | Yoo, Jeong-Ju | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Kim, Young Seok | - |
dc.date.accessioned | 2024-06-11T07:02:20Z | - |
dc.date.available | 2024-06-11T07:02:20Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 1010-660X | - |
dc.identifier.issn | 1648-9144 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25921 | - |
dc.description.abstract | Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab/bevacizumab. Results: VB occurred in two patients who showed good tumor response after atezolizumab/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations. In the first patient, VB did not occur as the tumor response decreased after a 50% reduction in bevacizumab. In the second patient, VB occurred again after a 50% bevacizumab reduction, so bevacizumab was discontinued and treatment with atezolizumab alone has been successfully maintained. Conclusions: Accordingly, we would like to suggest that considering bevacizumab dose reduction instead of changing to tyrosine kinase inhibitor may be a good clinical choice in atezolizumab/bevacizumab patients who develop VB. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/medicina60010157 | - |
dc.identifier.scopusid | 2-s2.0-85183091216 | - |
dc.identifier.wosid | 001151069100001 | - |
dc.identifier.bibliographicCitation | MEDICINA-LITHUANIA, v.60, no.1 | - |
dc.citation.title | MEDICINA-LITHUANIA | - |
dc.citation.volume | 60 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | upper gastrointestinal bleeding | - |
dc.subject.keywordAuthor | variceal bleeding | - |
dc.subject.keywordAuthor | adverse event | - |
dc.subject.keywordAuthor | bevacizumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.